市場調査レポート

製薬会社上位25社のパイプライン分析と売上高予測

Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2025

発行 Kalorama Information 商品コード 299928
出版日 ページ情報 英文 340 Pages
即納可能
価格
本日の銀行送金レート: 1USD=102.18円で換算しております。
Back to Top
製薬会社上位25社のパイプライン分析と売上高予測 Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2025
出版日: 2016年07月27日 ページ情報: 英文 340 Pages
概要

世界の医薬品市場では、近年数多くの重大な変化が起きており、そのなかには、市場の成長を妨げる方向に作用するものがある一方、新たなビジネスチャンスをもたらすようなものもあります。製薬業界は、人口の高齢化、傷病率の上昇、未対応の医療ニーズ、各国政府の動きなどマクロ経済面のさまざまな要因の影響を受けています。また、多くのブロックバスター製品が特許の期限切れを迎え、ジェネリック医薬品との競争に晒されるようになったことで、市場の様相は大きく変化しています。さらに、バイオテクノロジー開発への関心が高まったことで、これまで化学薬品が中心だった製薬業界の関心が生物学的治療にも向かうようになり、これが医療のさまざまな領域での大きな変化へとつながっています。

当レポートは、世界の製薬会社上位25社に注目し、各社の業績を分析するとともに、2025年までの売上高を予測したもので、売上高、研究開発支出、売上高の地域別内訳、個々の製品や各部門の業績、パイプラインの後期開発段階にある製品、成長戦略などの情報を盛り込んでお届けします。

エグゼクティブサマリー

  • イントロダクション
  • 調査範囲と方法
  • 将来的な市場機会
  • 主な企業
  • 結論

イントロダクション

  • 世界の医薬品市場
  • 製薬業界上位25社の概要
  • 世界の医療支出
  • 高齢化の進行と医薬品市場への影響

医薬品研究開発のトレンド

  • 医薬品研究開発の課題
  • 薬品承認プロセス
  • 承認率
  • より良い標的の選定
  • 研究開発支出の多い企業
  • パイプラインの概要
  • 広がる疾病治療の選択肢
  • バイオテクノロジーを利用した医薬品開発
  • 希少疾病用医薬品(オーファンドラッグ)
  • ファストトラック指定の医薬品
  • 医薬品承認の迅速化を目的とした各種の制度
  • 画期的な治療
  • 医薬品規制が認める独占権
  • 小児用医薬品の特許保護期間延長
  • 受託研究機関の役割

Pfizer, Inc.

Novartis International AG

Roche Ltd.

Merck & Co., Inc.

Sanofi

Gilead Sciences

Johnson & Johnson

GlaxoSmithKline plc

AstraZeneca plc

AbbVie, Inc.

Amgen, Inc.

TEVA Pharmaceutical Industries, Ltd.

Eli Lilly and Company

Bristol-Myers Squibb Company

Novo Nordisk

Bayer AG

武田薬品工業

Boehringer Ingelheim GmbH

Allergan PLC

アステラス製薬

Mylan, Inc.

Biogen, Inc.

Celgene Corporation

大塚製薬

第一三共

市場のサマリーと予測分析

  • 企業概要
  • 市場のトレンドと各分野の売上高
  • 心血管/血液
  • 神経治療
  • 感染症治療
  • 腫瘍
  • 呼吸器と炎症
  • 他の市場
  • 2015年に市場で起きた変化の評価
  • 対前年比成長率の分析
  • 企業分析
  • 市場予測
  • 各社の今後の展望

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: KLI15068137

The pharmaceutical market has witnessed a number of significant changes in recent years, providing both setbacks and new opportunities. The number of blockbuster pharmaceuticals reaching patent and exclusivity expiration status and vulnerable to generic competition has changed the landscape of the market for many manufacturers. The growing interest in biotechnology development has transitioned an industry once focused on chemical-based therapies to biologic therapies and produced exceptional changes in many areas of medical treatment over the last two decades. Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2025 examines the leaders in the pharmaceutical industry, including the late-term pipeline of major companies. This report provides long-term company sales forecasts based recent market conditions. For each company covered, the report provides:

  • Corporate Summary
  • Total Company Revenue and Total R&D Spending 2011-2015
  • Break-up of Sales by Region, 2015
  • Pharmaceutical Business Performance, 2011-2015 and Forecasted 2025
  • Pharmaceutical Segment Sales, 2011 through 2015 and Forecasted 2025
  • Leading Pharmaceutical Products, 2015 Sales
  • Late Stage Product Pipeline
  • Late Stage Product Pipeline by Therapeutic Area, Comparing 2009, 2011, 2013 and 2015
  • Corporate Development Details

The companies included in the study are:

  • AbbVie
  • Allergan
  • Amgen
  • Astellas
  • AstraZeneca
  • Bayer
  • Biogen
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Celgene Corp.
  • Daiichi Sankyo
  • Eli Lilly & Co.
  • Gilead Sciences
  • GlaxoSmithKline
  • Johnson & Johnson
  • Merck
  • Mylan
  • Novartis
  • Novo Nordisk
  • Otsuka Pharmaceutical
  • Pfizer
  • Roche
  • Sanofi
  • Takeda
  • TEVA

Despite the new approaches, new technologies and a wealth of new information, drug R&D is still challenged by understanding exactly how drugs will work and why they may fail. Target validation remains a quandary as well. Thus, the hurdle of getting past Phase III trials and launching more NMEs continues. Top 25 Pharmaceutical Company Pipeline Analysis and Sales Projections to 2025 provides a thorough discussion of current trends in pharmaceutical research and development, including:

  • Pharmaceutical Research & Development Challenge
  • The Drug Approval Process
  • Expanded Options in Treating Diseases
  • Biotechnology Drug Development
  • Orphan Drugs
  • Fast Track Drug Status
  • Other Accelerated Methods for Drug Approval
  • Pharmaceutical Regulatory Exclusivity
  • The Role of Contract Research Organizations

The report also looks at market trends and values by therapeutic area, providing information on the following segments:

  • Top 5 Cardiovascular/Blood Therapeutic Companies, 2015 Sales
  • Top 5 Neurotherapeutic Companies, 2015 Sales
  • Top 5 Infection Treatment Companies, 2015 Sales
  • Top 5 Oncology Companies, 2015 Sales
  • Top 5 Respiratory and Inflammation Product Companies, 2015 Sales
  • Top 5 Other Drug Companies, 2015 Sales

In addition to its company focus, the report examines the global pharmaceutical market, which has continued its recovery from the economic downfall experienced in recent years. Healthcare costs as a percent of GDP are increasing in almost all countries, though there are some exceptions. There are a number of macroeconomic concerns affecting sales such as aging populations, incidence of disease, unmet medical needs, government activities, and more. Data provided include:

  • Global Pharmaceutical Projects in Development by Therapeutic Segment
  • Global Pharmaceutical Market, 2011-2015 and Forecasted 2025
  • Global Pharmaceutical Market by Therapeutic Area, 2011-2015 and Forecasted 2025
  • Global Pharmaceutical Market % Change by Therapeutic Segment, 2014-2015
  • Top Pharmaceutical Companies, 1-25 by 2015 Pharmaceutical Sales
  • Top Companies by 2015 Pharmaceutical Sales Growth
  • Global Pharmaceutical Market, Sales Growth by Company, 2014- 2015
  • Top 25 Pharmaceutical Companies by Annual Pharmaceutical Sales, 2015 Compared to 2011 and 2013
  • Top 50 Pharmaceutical Products, by 2013 and 2015 Revenues
  • Global Pharmaceutical Market Forecast by Therapeutic Segment, 2025-based on late stage development projects evaluated
  • Evaluating Pharmaceutical Company Growth, 2015-2025
  • Total Healthcare Expenditures as a Percent of GDP by Country 2010 and 2015 Estimates (Australia, Austria, Canada, Czech Republic, Finland, France, Germany, Greece, Italy, Japan, Mexico, Switzerland, United Kingdom, United States)
  • International Population Trend Age 65+

For the purpose of this study, Kalorama Information has extracted sales for human pharmaceutical, including biopharmaceutical products. The market excludes consumer pharmaceuticals, diagnostics, devices, chemicals, agriculture and animal health. These are areas where many of these companies also compete with significant market shares.

Also, despite an in-depth interview process and complete review of company financials and literature, some variation in company rankings is possible. This is more likely with privately held companies or companies where prescription pharmaceutical sales are not discussed.

This report provides long-term company sales forecasts, which are based on 2015 market conditions. Company forecasts were derived from a combination of pipeline analyses, current product reviews, patent and exclusivity activities, recent merger and alliance impacts, and a number of other factors discovered throughout the writing of this report.

Table of Contents

ONE: Executive Summary

  • Introduction
  • Scope and Methodology
  • Future Market Opportunity
  • Leading Companies
  • Conclusions

TWO: Introduction

  • Global Pharmaceutical Market
  • Top 25 Pharmaceutical Companies: An Overview
  • Global Healthcare Spending
  • Aging Population and Impact on Pharmaceutical Markets

THREE: Trends in Pharmaceutical Research and Development

  • Pharmaceutical Research & Development Challenge
  • The Drug Approval Process
  • Percent of Approvals
  • Selecting Better Targets
  • Top R&D Spenders
  • The Pipeline Snapshot
  • Expanded Options in Treating Diseases
  • Biotechnology Drug Development
  • Orphan Drugs
  • Fast Track Drug Status
  • Other Accelerated Methods for Drug Approval
  • Breakthrough Therapy
  • Pharmaceutical Regulatory Exclusivity
  • Pediatric Extensions
  • The Role of Contract Research Organizations

FOUR: Pfizer, Inc.

  • Company Overview
  • Company Financial Performance and Investments
  • Geographic Market Participation
  • Pharmaceutical Business Performance
  • Leading Products
  • Late Stage Pipeline
  • Growth Strategy

FIVE: Novartis International AG

  • Company Overview
  • Company Financial Performance and Investments
  • Geographic Market Participation
  • Pharmaceutical Business Performance
  • Leading Products
  • Late Stage Pipeline
  • Growth Strategy

SIX: Roche Ltd.

  • Overview
  • Financial Performance and Investments
  • Geographic Market Participation
  • Pharmaceutical Business Performance
  • Leading Products
  • Late Stage Pipeline
  • Growth Strategy

SEVEN: Merck & Co., Inc.

  • Company Overview
  • Financial Performance and Investments
  • Geographic Market Participation
  • Pharmaceutical Business Performance
  • Leading Products
  • Late Stage Pipeline
  • Growth Strategy

EIGHT: Sanofi

  • Company Overview
  • Financial Performance and Investments
  • Geographic Market Participation
  • Pharmaceutical Business Performance
  • Leading Products
  • Late Stage Pipeline
  • Growth Strategy

NINE: Gilead Sciences

  • Company Overview
  • Company Financial Performance and Investments
  • Geographic Market Participation
  • Pharmaceutical Business Performance
  • Leading Products
  • Late Stage Pipeline
  • Growth Strategy

TEN: Johnson & Johnson

  • Company Overview
  • Financial Performance and Investments
  • Geographic Market Participation
  • Pharmaceutical Business Performance
  • Leading Products
  • Late Stage Pipeline
  • Growth Strategy

ELEVEN: GlaxoSmithKline plc

  • Company Overview
  • Financial Performance and Investments
  • Geographic Market Participation
  • Pharmaceutical Business Performance
  • Leading Products
  • Late Stage Pipeline
  • Growth Strategy

TWELVE: AstraZeneca plc

  • Company Overview
  • Financial Performance and Investments
  • Geographic Market Participation
  • Pharmaceutical Business Performance
  • Leading Products
  • Late Stage Pipeline
  • Growth Strategy

THIRTEEN: AbbVie, Inc.

  • Company Overview
  • Financial Performance and Investments
  • Pharmaceutical Business Performance
  • Leading Products
  • Late Stage Pipeline
  • Growth Strategy

FOURTEEN: Amgen, Inc.

  • Company Overview
  • Financial Performance and Investments
  • Geographic Market Participation
  • Pharmaceutical Business Performance
  • Leading Products
  • Late Stage Pipeline
  • Growth Strategy

FIFTEEN: TEVA Pharmaceutical Industries, Ltd.

  • Company Overview
  • Financial Performance and Investments
  • Geographic Market Participation
  • Pharmaceutical Business Performance
  • Leading Products
  • Late Stage Pipeline
  • Growth Strategy

SIXTEEN: Eli Lilly and Company

  • Company Overview
  • Financial Performance and Investments
  • Geographic Market Participation
  • Pharmaceutical Business Performance
  • Leading Products
  • Late Stage Pipeline
  • Growth Strategy

SEVENTEEN: Bristol-Myers Squibb Company

  • Company Overview
  • Company Financial Performance and Investments
  • Geographic Market Participation
  • Pharmaceutical Business Performance
  • Leading Products
  • Late Stage Pipeline
  • Growth Strategy

EIGHTEEN: Novo Nordisk

  • Company Overview
  • Financial Performance and Investments
  • Geographic Market Participation
  • Pharmaceutical Business Performance
  • Leading Products
  • Late Stage Pipeline
  • Growth Strategy

NINETEEN: Bayer AG

  • Company Overview
  • Company Financial Performance and Investments
  • Geographic Market Participation
  • Pharmaceutical Business Performance
  • Leading Products
  • Late Stage Pipeline
  • Growth Strategy

TWENTY: Takeda Pharmaceutical Co., Ltd.

  • Company Overview
  • Financial Performance and Investments
  • Geographic Market Participation
  • Pharmaceutical Business Performance
  • Leading Products
  • Late Stage Pipeline
  • Growth Strategy

TWENTY-ONE: Boehringer Ingelheim GmbH

  • Company Overview
  • Financial Performance and Investments
  • Geographic Market Participation
  • Pharmaceutical Business Performance
  • Leading Products
  • Late Stage Pipeline
  • Growth Strategy

TWENTY-TWO: Allergan PLC

  • Company Overview
  • Company Financial Performance and Investments
  • Pharmaceutical Business Performance
  • Late Stage Pipeline
  • Growth Strategy

TWENTY-THREE: Astellas Pharma, Inc.

  • Company Overview
  • Financial Performance and Investments
  • Geographic Market Participation
  • Pharmaceutical Business Performance
  • Leading Products
  • Late Stage Pipeline
  • Growth Strategy

TWENTY-FOUR: Mylan, Inc.

  • Company Overview
  • Company Financial Performance and Investments
  • Geographic Market Participation
  • Pharmaceutical Business Performance
  • Pipeline
  • Growth Strategy

TWENTY-FIVE: Biogen, Inc.

  • Company Overview
  • Company Financial Performance and Investments
  • Geographic Market Participation
  • Pharmaceutical Business Performance
  • Leading Products
  • Pipeline
  • Growth Strategy

TWENTY-SIX: Celgene Corporation

  • Company Overview
  • Company Financial Performance and Investments
  • Geographic Market Participation
  • Pharmaceutical Business Performance
  • Leading Products
  • Late Stage Pipeline
  • Growth Strategy

TWENTY-SEVEN: Otsuka Pharmaceutical

  • Company Overview
  • Financial Performance and Investments
  • Geographic Market Participation
  • Pharmaceutical Business Performance
  • Leading Products
  • Late Stage Pipeline
  • Growth Strategy

TWENTY-EIGHT: Daiichi Sankyo

  • Company Overview
  • Financial Performance and Investments
  • Geographic Market Participation
  • Pharmaceutical Business Performance
  • Leading Products
  • Late Stage Pipeline
  • Growth Strategy

TWENTY-NINE: Market Summary and Forecast Analysis

  • Company Overview
  • Market Trends and Values by Therapeutic Area
  • Cardiovascular/Blood Market Analysis
  • Neurotherapeutics Market Analysis
  • Infection Treatments Market Analysis
  • Oncology Market Analysis
  • Respiratory and Inflammation Market Analysis
  • Other Drug Market Analysis
  • Evaluating Changes in 2015 Market Value
  • Year-over-Year Growth Analysis
  • Company Analysis
  • Market Forecast
  • Future Company Outlook

LIST OF EXHIBITS

ONE: Executive Summary

  • Table 1-1: Global Pharmaceutical Projects in Development by Therapeutic Segment
  • Figure 1-1: Global Pharmaceutical Market, 2011-2015 and Forecasted 2025
  • Table 1-2: Leading Pharmaceutical Companies

TWO: Introduction

  • Figure 2-1: Global Pharmaceutical Market by Therapeutic Area, 2011-2015 and Forecasted 2025
  • Table 2- 1: Top Pharmaceutical Companies, 1-25 by 2015 Pharmaceutical Sales
  • Figure 2-2: Top 25 Pharmaceutical Companies by Annual Pharmaceutical Sales2015
  • Table 2-2: Total Healthcare Expenditures as a Percent of GDP by Country 2010 and 2015 Estimates
  • Figure 2-3: International Population Trend Age 65+

THREE: Trends in Pharmaceutical Research and Development

  • Table 3-1: Phases of Clinical Drug Development
  • Table 3-2: Top R&D Spenders in the Pharmaceutical Industry 2013, 2014 and2015
  • Figure 3-1: Top 10 R&D Spenders in the Pharmaceutical Industry, 2015 Comparison by Company
  • Figure 3-2: Company Pipelines by Total Late Stage Development Projects (Top 25 Companies by Revenues)
  • Figure 3-3: Cardiovascular/Blood Pipeline Leaders, 2015
  • Figure 3-4: Neurotherapeutics Pipeline Leaders, 2015
  • Figure 3-5: Infectious Disease Pipeline Leaders, 2015
  • Figure 3-6: Oncology Pipeline Leaders, 2015
  • Figure 3-7: Respiratory/Inflammation Pipeline Leaders, 2015
  • Figure 3-8: Other Therapy Pipeline Leaders, 2015
  • Table 3-3: Orphan Drug Designations Granted and Approved by the FDA 1983-2016
  • Table 3-4: Examples of Fast-Track Drugs Withdrawn from Market

FOUR: Pfizer, Inc.

  • Table 4-1: Pfizer Corporate Summary
  • Table 4-2: Pfizer: Total Company Revenue and Total R&D Spending 2011-2015
  • Figure 4-1: Pfizer: Break-up of Total Revenues by Region, 2015
  • Figure 4-2: Pfizer: Pharmaceutical Business Performance, 2011-2015 and Forecasted 2025
  • Figure 4-3: Pfizer: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025
  • Table 4-3: Pfizer: Leading Pharmaceutical Products, 2015 Sales
  • Table 4-4: Pfizer: Late Stage Product Pipeline
  • Figure 4-4: Pfizer: Late Stage Product Pipeline by Therapeutic Area Comparing 2009, 2011, 2013 and 2015
  • Table 4-5: Highlighted Corporate Developments

FIVE: Novartis International AG

  • Table 5-1: Novartis Corporate Summary
  • Table 5-2: Novartis: Total Company Revenue and Total R&D Spending 2011-2015
  • Figure 5-1: Novartis: Break-up of Sales by Region, 2015
  • Figure 5-2: Novartis: Pharmaceutical Business Performance, 2011-2015 and Forecasted 2025
  • Figure 5-3: Novartis: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025
  • Table 5-3: Novartis: Leading Pharmaceutical Products, 2015 Sales
  • Table 5-4: Novartis: Late Stage Product Pipeline
  • Figure 5-4: Novartis: Late Stage Product Pipeline by Therapeutic Area-Comparing 2009, 2011, 2013 and 2015
  • Table 5-5: Highlighted Corporate Developments

SIX: Roche Ltd.

  • Table 6-1: Roche Corporate Summary
  • Table 6-2: Roche: Total Company Revenue and Total R&D Spending 2011-2015
  • Figure 6-1: Roche: Break-up of Sales by Region, 2015
  • Figure 6-2: Roche: Pharmaceutical Business Performance, 2011-2015 and Forecasted 2025
  • Figure 6-3: Roche: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025
  • Table 6-3: Roche: Leading Pharmaceutical Products, 2015 Sales
  • Table 6-4: Roche: Late Stage Product Pipeline
  • Figure 6-4: Roche: Late Stage Product Pipeline by Therapeutic Area-Comparing 2009, 2011, 2013 and 2015
  • Table 6-5: Highlighted Corporate Developments

SEVEN: Merck & Co., Inc.

  • Table 7-1: Merck Corporate Summary
  • Table 7-2: Merck: Total Company Revenue and Total R&D Spending 2011-2015
  • Figure 7-1: Merck: Break-up of Sales by Region, 2015
  • Figure 7-2: Merck: Pharmaceutical Business Performance, 2011-2015 and Forecasted 2025
  • Figure 7-3: Merck: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025
  • Table 7-3: Merck: Leading Pharmaceutical Products, 2015 Sales
  • Table 7-4: Merck: Late Stage Product Pipeline
  • Figure 7-4: Merck: Late Stage Product Pipeline by Therapeutic Area-Comparing 2009, 2011, 2013 and 2015
  • Table 7-5: Highlighted Corporate Developments

EIGHT: Sanofi

  • Table 8-1: Sanofi Corporate Summary
  • Table 8-2: Sanofi Total Company Revenue and Total R&D Spending 2011-2015
  • Figure 8-1: Sanofi: Break-up of Sales by Region, 2015
  • Figure 8-2: Sanofi: Pharmaceutical Business Performance, 2011-2015 and Forecasted 2025
  • Figure 8-3: Sanofi: Pharmaceutical Segment Sales - 2011 through 2015 and Forecasted 2025
  • Table 8-3: Sanofi: Leading Pharmaceutical Products, 2015 Sales
  • Table 8-4: Sanofi Late Stage Product Pipeline
  • Figure 8-4: Sanofi: Late Stage Product Pipeline by Therapeutic Area Comparing 2009, 2011, 2013 and 2015
  • Table 8-5: Highlighted Corporate Developments

NINE: Gilead Sciences

  • Table 9-1: Gilead Sciences Corporate Summary
  • Table 9-2: Gilead Sciences: Total Company Revenue and Total R&D Spending2011-2015
  • Figure 9-1: Gilead Sciences: Break-up of Sales by Region, 2015
  • Figure 9-2: Gilead Sciences: Pharmaceutical Business Performance, 2011-2015 and Forecasted 2025
  • Figure 9-3: Gilead Sciences: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025
  • Table 9-3: Gilead Sciences: Leading Pharmaceutical Products, 2015 Sales
  • Table 9-4: Gilead Sciences: Late Stage Product Pipeline
  • Figure 9-4: Gilead Sciences: Late Stage Product Pipeline by Therapeutic Area Comparing 2009, 2011, 2013 and 2015
  • Table 9-5: Gilead Sciences: Highlighted Corporate Developments

TEN: Johnson & Johnson

  • Table 10-1: Johnson & Johnson Corporate Summary
  • Table 10-2: Johnson & Johnson: Total Company Revenue and Total R&D Spending 2011-2015
  • Figure 10-1: Johnson & Johnson: Break-up of Sales by Region, 2015
  • Figure 10-2: Johnson & Johnson: Pharmaceutical Business Performance, 2011-2015 and Forecasted 2025
  • Figure 10-3: Johnson & Johnson: Pharmaceutical Segment Sales 2011 through2015 and Forecasted 2025
  • Table 10-3: Johnson & Johnson: Leading Pharmaceutical Products, 2015 Sales
  • Table 10-4: Johnson & Johnson: Late Stage Product Pipeline
  • Figure 10-4: Johnson & Johnson: Late Stage Product Pipeline by Therapeutic Area-Comparing 2009, 2011, 2013 and 2015
  • Table 10-5: Highlighted Corporate Developments

ELEVEN: GlaxoSmithKline plc

  • Table 11-1: GlaxoSmithKline Corporate Summary
  • Table 11-2: GlaxoSmithKline: Total Company Revenue and Total R&D Spending2011-2015
  • Figure 11-1: GlaxoSmithKline: Break-up of Sales by Region, 2015
  • Figure 11-2: GlaxoSmithKline: Pharmaceutical Business Performance, 2011-2015 and Forecasted 2025
  • Figure 11-3: GlaxoSmithKline: Pharmaceutical Segment Sales 2011 through2015 and Forecasted 2025
  • Table 11-3: GlaxoSmithKline: Leading Pharmaceutical Products, 2015 Sales
  • Table 11-4: GlaxoSmithKline: Late Stage Product Pipeline
  • Figure 11-4: GlaxoSmithKline: Late Stage Product Pipeline by Therapeutic Area-Comparing 2009, 2011, 2013 and 2015
  • Table 11-5: Highlighted Corporate Developments

TWELVE: AstraZeneca plc

  • Table 12-1: AstraZeneca Corporate Summary
  • Table 12-2: AstraZeneca: Total Company Revenue and Total R&D Spending2011-2015
  • Figure 12-1: AstraZeneca: Break-up of Sales by Region, 2015
  • Figure 12-2: AstraZeneca: Pharmaceutical Business Performance, 2011-2015 and Forecasted 2025
  • Figure 12-3: AstraZeneca: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025
  • Table 12-3: AstraZeneca: Leading Pharmaceutical Products, 2015 Sales
  • Table 12-4: AstraZeneca: Late Stage Product Pipeline
  • Figure 12-4: AstraZeneca: Late Stage Product Pipeline by Therapeutic Area-Comparing 2009, 2011, 2013and 2015
  • Table 12-5: Highlighted Corporate Developments

THIRTEEN: AbbVie, Inc.

  • Table 13-1: AbbVie Corporate Summary
  • Table 13-2: AbbVie: Total Company Revenue and Total R&D Spending 2011-2015
  • Figure 13-1: AbbVie: Pharmaceutical Business Performance, 2011-2015 and Forecasted 2025
  • Figure 13-2: AbbVie: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025
  • Table 13-3: AbbVie: Leading Pharmaceutical Products, 2015 Sales
  • Table 13-4: AbbVie: Late Stage Product Pipeline
  • Figure 13-3: AbbVie: Late Stage Product Pipeline by Therapeutic Area-Comparing 2009, 2011, 2013 and 2015
  • Table 13-5: Highlighted Corporate Developments

FOURTEEN: Amgen, Inc.

  • Table 14-1: Amgen Corporate Summary
  • Table 14-2: Amgen: Total Company Revenue and Total R&D Spending 2011-2015
  • Figure 14-1: Amgen: Break-up of Sales by Region, 2015
  • Figure 14-2: Amgen: Pharmaceutical Business Performance, 2011-2015 and Forecasted 2025
  • Figure 14-3: Amgen: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025
  • Table 14-3: Amgen: Leading Pharmaceutical Products, 2015 Sales
  • Table 14-4: Amgen: Late Stage Product Pipeline
  • Figure 14-4: Amgen: Late Stage Product Pipeline by Therapeutic Area-Comparing 2009, 2011, 2013 and 2015
  • Table 14-5: Highlighted Corporate Developments

FIFTEEN: TEVA Pharmaceutical Industries, Ltd.

  • Table 15-1: Teva Pharmaceutical Corporate Summary
  • Table 15-2: Teva Pharmaceutical: Total Company Revenue and Total R&D Spending 2011-2015
  • Figure 15-1: Teva Pharmaceutical: Break-up of Sales by Region, 2015
  • Figure 15-2: Teva Pharmaceutical: Pharmaceutical Business Performance, 2011-2015 and Forecasted 2025
  • Figure 15-3: Teva Pharmaceutical: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025
  • Table 15-3: Teva Pharmaceutical: Leading Pharmaceutical Products, 2015 Sales
  • Table 15-4: Teva Pharmaceutical: Late Stage Product Pipeline-Brand Development
  • Figure 15-4: Teva Pharmaceutical: Late Stage Product Pipeline by Therapeutic Area (Brand Therapeutics)-Comparing 2009, 2011, 2013 and 2015
  • Table 15-5: Highlighted Corporate Developments

SIXTEEN: Eli Lilly and Company

  • Table 16-1: Eli Lilly Corporate Summary
  • Table 16-2: Eli Lilly's Total Company Revenue and Total R&D Spending 2011-2015
  • Figure 16-1: Eli Lilly & Co.: Break-up of Sales by Region, 2015
  • Figure 16-2: Eli Lilly & Co.: Pharmaceutical Business Performance, 2011-2015 and Forecasted 2025
  • Figure 16-3: Eli Lilly & Co.: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025
  • Table 16-3: Eli Lilly & Co.: Leading Pharmaceutical Products, 2015 Sales
  • Table 16-4: Eli Lilly: Late Stage Product Pipeline
  • Figure 16-4: Eli Lilly & Co.: Late Stage Product Pipeline by Therapeutic Area-Comparing 2009, 2011, 2013 and 2015
  • Table 16-5: Highlighted Corporate Developments

SEVENTEEN: Bristol-Myers Squibb Company

  • Table 17-1: Bristol-Myers Squibb Corporate Summary
  • Table 17-2: Bristol-Myers Squibb's Total Company Revenue and Total R&D Spending 2011-2015
  • Figure 17-1: Bristol-Myers Squibb: Break-up of Sales by Region, 2015
  • Figure 17-2: Bristol-Myers Squibb: Pharmaceutical Business Performance, 2011-2015 and Forecasted 2025,($millions)
  • Figure 17-3: Bristol-Myers Squibb: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025
  • Table 17-3: Bristol-Myers Squibb: Leading Pharmaceutical Products, 2015 Sales
  • Table 17-4: Bristol-Myers Squibb: Late Stage Product Pipeline
  • Table 17-5: Bristol-Myers Squibb Highlighted Corporate Developments

EIGHTEEN: Novo Nordisk

  • Table 18-1: Novo Nordisk Corporate Summary
  • Table 18-2: Novo Nordisk: Total Company Revenue and Total R&D Spending 2011-2015
  • Figure 18-1: Novo Nordisk: Break-up of Sales by Region, 2015
  • Figure 18-2: Novo Nordisk: Pharmaceutical Business Performance, 2011-2015 and Forecasted 2025
  • Figure 18-3: Novo Nordisk: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025
  • Table 18-3: Novo Nordisk: Leading Pharmaceutical Products, 2015 Sales
  • Table 18-4: Novo Nordisk: Late Stage Product Pipeline
  • Figure 18-4: Novo Nordisk: Late Stage Product Pipeline by Therapeutic Area-Comparing 2009, 2011, 2013 and 2015
  • Table 18-5: Highlighted Corporate Developments

NINETEEN: Bayer AG

  • Table 19-1: Bayer Corporate Summary
  • Table 19-2: Bayer's Total Company Revenue and Total R&D Spending 2011-2015
  • Figure 19-1: Bayer: Break-up of Sales by Region, 2015
  • Figure 19-2: Bayer: Pharmaceutical Business Performance, 2011-2015 and Forecasted 2025
  • Figure 19-3: Bayer: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025
  • Table 19-3: Bayer: Leading Pharmaceutical Products, 2015 Sales
  • Table 19-4: Bayer: Late Stage Product Pipeline
  • Figure 19-4: Bayer: Late Stage Product Pipeline by Therapeutic Area-Comparing 2009, 2011, 2013 and 2015
  • Table 19-5: Highlighted Corporate Developments

TWENTY: Takeda Pharmaceutical Co., Ltd.

  • Table 20-1: Takeda Corporate Summary
  • Table 20-1: Takeda's Total Company Revenue and Total R&D Spending 2011-2015
  • Figure 20-1: Takeda: Break-up of Sales by Region, 2015
  • Figure 20-2: Takeda: Pharmaceutical Business Performance, 2011-2015 and Forecasted 2025
  • Figure 20-3: Takeda: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025
  • Table 20-3: Takeda: Leading Pharmaceutical Products, 2015 Sales
  • Table 20-4: Takeda Pharmaceutical: Late Stage Product Pipeline
  • Figure 20-4: Takeda: Late Stage Product Pipeline by Therapeutic Area-Comparing 2009, 2011, 2013 and 2015
  • Table 20-5: Highlighted Corporate Developments

TWENTY-ONE: Boehringer Ingelheim GmbH

  • Table 21-1: Boehringer Ingelheim Corporate Summary
  • Table 21-2: Boehringer Ingelheim: Total Company Revenue and Total R&D Spending 2011-2015
  • Figure 21-1: Boehringer Ingelheim: Break-up of Sales by Region, 2015
  • Figure 21-2: Boehringer Ingelheim: Pharmaceutical Business Performance, 2011-2015 and Forecasted 2025
  • Figure 21-3: Boehringer Ingelheim: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025
  • Table 21-3: Boehringer Ingelheim: Leading Pharmaceutical Products, 2015 Sales
  • Table 21-4: Boehringer Ingelheim: Late Stage Product Pipeline
  • Figure 21-4: Boehringer Ingelheim: Late Stage Product Pipeline by Therapeutic Area-Comparing 2009, 2011, 2013 and 2015
  • Table 21-5: Highlighted Corporate Developments

TWENTY-TWO: Allergan PLC

  • Table 22-1: Allergan plc Corporate Summary
  • Table 22-2: Allergan: Total Company Revenue and Total R&D Spending 2011-2015
  • Figure 22-1: Allergan: Pharmaceutical Business Performance, 2014-2015 and Forecasted 2025
  • Figure 22-2: Allergan: Pharmaceutical Segment Sales 2014 - 2015 and Forecasted 2025
  • Table 22-3: Allergan: Late Stage Product Pipeline-Brand Development
  • Table 22-4: Allergan: Highlighted Corporate Developments

TWENTY-THREE: Astellas Pharma, Inc.

  • Table 23-1: Astellas Corporate Summary
  • Table 23-2: Astellas: Total Company Revenue and Total R&D Spending 2011-2015
  • Figure 23-1: Astellas: Break-up of Sales by Region, 2015
  • Figure 23-2: Astellas: Pharmaceutical Business Performance, 2011-2015 and Forecasted 2025
  • Figure 23-3: Astellas: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025
  • Table 23-3: Astellas: Leading Pharmaceutical Products, 2015 Sales
  • Table 23-4: Astellas: Late Stage Product Pipeline
  • Figure 23-4: Astellas: Late Stage Product Pipeline by Therapeutic Area-Comparing 2009, 2011, 2013 and 2015
  • Table 23-5: Highlighted Corporate Developments

TWENTY-FOUR: Mylan, Inc.

  • Table 24-1: Mylan Corporate Summary
  • Table 24-2: Mylan: Total Company Revenue and Total R&D Spending 2011-2015
  • Figure 24-1: Mylan: Break-up of Sales by Region, 2015
  • Figure 24-2: Mylan: Pharmaceutical Business Performance, 2011-2015 and Forecasted 2025
  • Figure 24-3: Mylan: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025
  • Table 24-4: Corporate Development Details

TWENTY-FIVE: Biogen, Inc.

  • Table 25-1: Biogen Corporate Summary
  • Table 25-2: Biogen: Total Company Revenue and Total R&D Spending 2011-2015
  • Figure 25-1: Biogen: Break-up of Sales by Region, 2015
  • Figure 25-2: Biogen: Pharmaceutical Business Performance, 2011-2015 and Forecasted 2025
  • Figure 25-3: Biogen: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025
  • Table 25-3: Biogen: Leading Pharmaceutical Products, 2015 Sales
  • Table 25-4: Biogen: Late Stage Product Pipeline
  • Figure 25-4: Biogen: Late Stage Product Pipeline by Therapeutic Area-Comparing 2009, 2011 and 2013
  • Table 25-5: Biogen: Highlighted Corporate Developments

TWENTY-SIX: Celgene Corporation

  • Table 26-1: Celgene Corporate Summary
  • Table 26-2: Celgene: Total Company Revenue and Total R&D Spending 2011-2015
  • Figure 26-1: Celgene: Break-up of Sales by Region, 2015
  • Figure 26-2: Celgene: Pharmaceutical Business Performance, 2011-2015 and Forecasted 2025
  • Figure 26-3: Celgene: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025
  • Table 26-3: Celgene: Leading Pharmaceutical Products, 2015 Sales
  • Table 26-4: Celgene: Late Stage Product Pipeline
  • Figure 26-4: Celgene: Late Stage Product Pipeline by Therapeutic Area-Comparing 2009, 2011, 2013 and 2015
  • Table 26-5: Celgene: Corporate Development Details

TWENTY-SEVEN: Otsuka Pharmaceutical

  • Table 27-1: Otsuka Corporate Summary
  • Table 27-2: Otsuka Holdings: Total Company Revenue and Total R&D Spending2011-2015
  • Figure 27-1: Otsuka Holdings: Break-up of Sales by Region, 2015
  • Figure 27-2: Otsuka Holdings: Pharmaceutical Business Performance, 2011-2015 and Forecasted 2023
  • Figure 27-3: Otsuka Holdings: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025
  • Table 27-3: Otsuka Holdings: Leading Pharmaceutical Products, 2015 Sales
  • Table 27-4: Otsuka Holdings: Late Stage Product Pipeline
  • Figure 27-4: Otsuka Holdings: Late Stage Product Pipeline by Therapeutic Area-Comparing 2009, 2011, 2013 and 2015
  • Table 27-5: Highlighted Corporate Developments

TWENTY-EIGHT: Daiichi Sankyo

  • Table 28-1: Daiichi Sankyo Corporate Summary
  • Table 28-2: Daiichi Sankyo: Total Company Revenue and Total R&D Spending2011-2015
  • Figure 28-1: Daiichi Sankyo: Break-up of Sales by Region, 2015
  • Figure 28-2: Daiichi Sankyo: Pharmaceutical Business Performance, 2011-2015 and Forecasted 2025
  • Figure 28-3: Daiichi Sankyo: Pharmaceutical Segment Sales 2011 through 2015 and Forecasted 2025
  • Table 28-3: Daiichi Sankyo: Leading Pharmaceutical Products, 2015 Sales
  • Table 28-4: Daiichi Sankyo: Late Stage Product Pipeline
  • Figure 28-4: Daiichi Sankyo: Late Stage Product Pipeline by Therapeutic Area-Comparing 2009, 2011, 2013 and 2015
  • Table 28-5: Highlighted Corporate Developments

TWENTY-NINE: Market Summary and Forecast Analysis

  • Table 29-1: Global Pharmaceutical Market, 2011-2015 and Forecasted 2025
  • Figure 29-1: Global Pharmaceutical Market, 2011-2015 and Forecasted 2025
  • Figure 29-2: Global Pharmaceutical Market by Therapeutic Area, 2011-2015 and Forecasted 2025
  • Figure 29-3: Top 5 Cardiovascular/Blood Therapeutic Companies, 2015 Sales
  • Figure 29-4: Top 5 Neurotherapeutic Companies, 2015 Sales
  • Figure 29-5: Top 5 Infection Treatment Companies, 2015 Sales
  • Figure 29-6: Top 5 Oncology Companies, 2015 Sales
  • Figure 29-6: Top 5 Respiratory and Inflammation Product Companies, 2015 Sales
  • Figure 29-7: Top 5 Other Drug Companies, 2015 Sales
  • Figure 29-8: Global Pharmaceutical Market % Change by Therapeutic Segment,2014- 2015
  • Table 29-2: Top Companies by 2015 Pharmaceutical Sales Growth
  • Figure 29-9: Global Pharmaceutical Market, Sales Growth by Company, 2014-2015
  • Table 29-3: Top 25 Pharmaceutical Companies by Annual Pharmaceutical Sales2015 Compared to 2011 and 2013
  • Table 29-4: Top 50 Pharmaceutical Products, by 2013 and 2015 Revenues
  • Table 29-5: Global Pharmaceutical Market Forecast by Therapeutic Segment,2025-based on late stage development projects evaluated
  • Figure 29-11: Global Pharmaceutical Market Forecast by Therapeutic Segment,2025-based on late stage development projects evaluated
  • Table 29-6: Evaluating Pharmaceutical Company Growth, 2015-2025
Back to Top